Kornimate/medical-research-clean huggingface dataset:
an european union (eu) post-approval registry of the treo® stent-graft

Conditions: Aortic Aneurysm, Abdominal

Summary: this is an eu sponsored trial and independent of the us trial registered under clinicaltrials.gov id nct02009644. the purpose of this registry is to gather clinical data on the safety and performance of the treo stent-graft in patients with infrarenal abdominal aortic aneurysms. the registry is part of treo's eu post-market surveillance plan providing long-term systematic clinical follow-up.

this is a prospective, multicenter, post-market clinical follow-up, non-randomized registry of the treo stent-graft. subjects diagnosed with infrarenal aortic aneurysms and treated with the treo stent-graft or treo aorto-uni-iliac (aui) device can be included into the registry. pre-procedure baseline data will be gathered as well as post-procedure assessments prior to hospital discharge and one to three months and 1, 2, 3, 4, and 5-year post-implantation. the objective of the registry is to assess the clinical results and health economics of the treo device in a real-world population of patients with infrarenal abdominal aortic aneurysms (aaa).

Eligibility criteria:
inclusion criteria: * age \> 18 years * signed informed consent * willingness to comply with study follow-up * indication for elective endovascular repair * planned implantation of single treo device system or aorto uni-iliac (aui) device to include any auxiliary device components exclusion criteria: * intolerance to contrast media * emergency procedure * chimneys or fenestrated device procedures * connective tissue disease (e.g., marfan's syndrome) * high probability of non-adherence to follow-up requirements * current participation in a concurrent trial that may confound study results * female of childbearing potential in whom pregnancy cannot be excluded * previous endovascular or surgical aaa repair

Keywords: aaa abdominal aortic aneurysms
impact of preoperative hba1c levels on pathologic features and oncological outcomes in the patients with prostate cancer

Conditions: Prostate Neoplasm; Pathology

Summary: the effect of preoperative glycemic control measured by hba1c on prostate cancer (pca) outcome remains controversial. thus, the investigators aim to examine the association of preoperative glycemic control with oncologic outcomes after radical prostatectomy (rp). the investigators will prospectively collect the relevant data including preoperative hba1c in 264 patients of pca patients undergoing rp. the associations between clinical variables and risk of adverse pathological features and disease recurrence will be tested using a multivariate logistic regression and multiple cox-proportional hazards model, respectively.

* this is the observational study as the single institutional, prospective cohort study. the investigators prospectively collect the clinicopathological information of the patients with prostate cancer (pca) undergoing radical prostatectomy (rp). * particularly, the investigators check the variables, including age at surgery, body mass index, comorbidities, preoperative psa levels, prostate volume measured by trus, preoperative hba1c levels, biopsy gleason score, positive biopsy cores, percent positive cores, clinical tmn staging, final pathological results (tmn stage, gleason score, extraprostatic extension, seminal vesicle invasion, surgical margin positivity, postoperative biochemical recurrence (bcr), local recurrence, and distant metastasis during follow-up periods. * the study protocol is same with routine follow-up schedule of the patients with pca treated with rp. typically, the investigators check the patients at 1, 3, 6, 9, 12, 18, 24, 30 and 36 months. however, according to the patients status and preference, follow-up schedule can be changed within 3 months at specific time points. because the present study is the observational cohort study, not intervention study, subtle changes of follow-up schedule would not affect on the primary outcomes. * importantly, preoperative hba1c should be checked within 1 month before operation, same as the routine preoperative laboratory tests.

Eligibility criteria:
inclusion criteria: * prostate cancer diagnosed with prostate biopsy * clinically localized pca confirmed by prostate mri and bone scan * patients undergoing rp exclusion criteria: * distant metastasis, preoperatively * preoperative hormone therapy * preoperative chemotherapy * radiation therapy * medications affecting glucose status other than diabetes mellitus

Keywords: prostate cancer preoperative glycemic control hemoglobin a1c pathologic outcomes oncological outcomes treatment outcome hemoglobin a1c protein, human
mobile thinking intervention: a inital test

Conditions: Schizophrenia; Clinical High Risk for Psychosis (CHR)

Summary: this study will test the inital efficacy of a brief mobile intervention targeting biased thinking.


Eligibility criteria:
inclusion criteria: * diagnosis of schizophrenia or related psychotic disorder or * identified as being at clinical high risk for psychosis in symptom interviews exclusion criteria: * recent changes in mental health treatment in past month or two months if on depot
prospective validation of the deva algorithm for the prediction of severe endometriosis

Conditions: Endometriosis

Summary: endometriosis is a chronic disease affecting 1 in 10 women. its diagnosis is difficult and the time between the first symptoms and diagnosis is of about 7 years. diagnosis requires specialized imaging performed by referral practitioners for this pathology. according to current recommendations, non-specialized pelvic ultrasound is the recommended first-line examination. however, only reference ultrasound, performed by a doctor specialized in the disease and carried out according to a specific protocol (such as ubess), is sufficiently reliable for diagnosis. the number of practitioners performing this type of examination is very low in france, which in practice results in a very low reliability of this strategy in real life. pelvic mri is also a much more reliable examination, available for review. however its access is limited. in addition, the false positive rate can be as high as 20%, particularly for minor forms of the disease. the deva algorithm has been developed for the identification of women with endometriosis based on a self-administered pelvic pain symptom questionnaire (endopain). in a preliminary study, this algorithm seems reliable for identify patients at high risk of this disease and would thus allow to triage patients requiring patients requiring an immediate mri in order to shorten diagnostic delays. external validation of the algorithm is therefore necessary before clinical use. the main objective od this study is the prospective external validation of the diagnostic reliability of the deva algorithm used for the detection of women with endometriosis (visible on mri or transvaginal ultrasound).


Eligibility criteria:
inclusion criteria: * female patients * patients aged 18-45 * patients addressed for an pelvic irm or transvaginal echography exclusion criteria: * minor patients * patients over 45 years of age * patients without social security * patients that do not know how to read in french * patients with a chronic pathology responsible of pain or handicap * patients with a major pelvic pathology * patients with more than 3 months of amenorrhea * patients diagnosed or suspicious of having an invasive cancer.
efficacy of pennsaid® for pain management in the emergency department

Conditions: Pain; Ankle Sprain

Summary: the primary objective of this study is to compare the pain relieving effect and speed of onset of pennsaid to that of standard oral diclofenac under double blind conditions using a growth curve approach to pain measurement. the investigators will test the hypothesis that pennsaid will provide more rapid pain relief than oral diclofenac during the ed visit. the secondary goal of the proposed work is to discover and model the onset and course of pain relief during the emergency department (ed) visit.


Eligibility criteria:
inclusion: -we will include ed patients presenting with an acutely painful ankle sprain for which nsaids constitute standard of care pain management. the following will be excluded: * those with lacerations, bites, burns * any head trauma * pregnant * anyone with a pre-existing chronic pain condition * inflammatory intestinal disorders such as crohn's disease or ulcerative colitis * anyone regularly using another nsaid or anti-coagulation medication * anyone who has experienced asthma after nsaid use * compromised cognitive abilities * a significant co-morbidity that will compromise participation * had joint replacements * known hypersensitivity to diclofenac or allergic responses to nsaids as a class * active stomach and/or duodenal ulceration or gastrointestinal bleeding * anyone admitted with severe active bleeding * recent heart surgery * severe liver or renal insufficiency * prisoner * mentally disabled patients * wards of the state * cognitive or decisional impairment

Keywords: pain management
pathway of dyspneic patient in emergency (paradise)

Conditions: Dyspnea; Cardiac; Acute Disease

Summary: this is an observational retrospective single-center study (chru of nancy) in patients cared for acute dyspnea by a medical team of the emergencies of the chru of nancy. the main purpose of the study is to evaluate the outcome of patients cared for acute dyspnea by a medical team of emergencies of chru of nancy.

this observational retrospective single-center study will be conducted using data from medical records, acquired as part of usual care, patients cared for acute dyspnea in the last 5 years (from the date of authorization of data processing). about 4,000 patients will be affected, including more than 800 patients with acute heart failure.

Eligibility criteria:
inclusion criteria: * man or women ≥ 18 years * patients with acute dyspnea cared by a medical team of the emergencies of chru of nancy. exclusion criteria: * cardiorespiratory arrest before the care by a medical team of the emergencies of the chru of nancy.

Keywords: acute dyspnea emergency acute heart failure
interleukin-2 plus bryostatin 1 in treating patients with melanoma or kidney cancer

Conditions: Kidney Cancer; Melanoma (Skin)

Summary: rationale: drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. interleukin-2 may stimulate a person's white blood cells to kill tumor cells. combining bryostatin 1 with interleukin-2 may kill more tumor cells. purpose: randomized phase i trial to study the effectiveness of interleukin-2 plus bryostatin 1 in treating patients who have melanoma or kidney cancer that cannot be removed during surgery.

objectives: * determine the dose of bryostatin 1 that, when administered in conjunction with low-dose interleukin-2, maximizes in vitro interleukin-2- stimulated peripheral blood stem cell proliferation in patients with melanoma or renal cell carcinoma. * assess other intermediate markers of immune response in patients treated with this regimen. * determine tumor responses, response durations, progression-free intervals, and survival of patients treated with this regimen. outline: this is a randomized, double-blind study. patients are randomized to one of three bryostatin 1 dose levels. patients receive interleukin-2 subcutaneously daily on days 1-5 and bryostatin 1 iv over 1 hour on day 1 weekly for 3 weeks. courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity. patients are followed every 3 months. projected accrual: a total of 21 patients will be accrued for this study within 2 years.

Eligibility criteria:
disease characteristics: * histologically or cytologically confirmed cutaneous or mucosal melanoma or renal cell carcinoma * unresectable disease * no known uncontrolled cns metastases * cns metastases allowed only if recently irradiated or known to be controlled patient characteristics: age: * 18 and over performance status: * ecog 0-1 life expectancy: * not specified hematopoietic: * hemoglobin at least 8 g/dl * wbc at least 3,000/mm\^3 * platelet count at least 100,000/mm\^3 * absolute lymphocyte count at least 1,000/mm\^3 hepatic: * total bilirubin no greater than 1.5 mg/dl or * conjugated bilirubin no greater than 0.3 mg/dl * ast no greater than 2.5 times upper limit of normal renal: * creatinine no greater than 2 mg/dl cardiovascular: * no myocardial infarction within the past 6 months * no uncontrolled hypertension, angina, or congestive heart failure other: * not pregnant or nursing * fertile patients must use effective contraception during and for 3 months after study * no known intolerance to acetaminophen * no primary or secondary immunodeficiency * no other condition that would preclude study prior concurrent therapy: biologic therapy: * not specified chemotherapy: * not specified endocrine therapy: * at least 1 month since prior topical, systemic, or inhaled corticosteroids * no concurrent topical, systemic, or inhaled corticosteroids radiotherapy: * see disease characteristics surgery: * not specified

Keywords: stage iii renal cell cancer stage iv renal cell cancer recurrent renal cell cancer stage iii melanoma stage iv melanoma recurrent melanoma
comparison of efficiency between i-gel blind intubation and i-gel bronchoscopic intubation during resuscitation

Conditions: Heart Arrest

Summary: the investigators will compare conventional intubation using macintosh laryngoscope, blind endotracheal intubation using i-gel for conduit and bronchoscopic intubation using ambu-ascope and i-gel. all situation assumed as cardiac arrest. i.e, someone give chest compressions continuously without interruption. moreover the investigators will compare the type of endotracheal tube. reinforced tube has more soft tube tip, so the investigators think it is more acceptable for intubation using i-gel as conduit.


Eligibility criteria:
inclusion criteria: * emergency physician * work at emergency department more than 1 year. * 50 or more experience of endotracheal intubation exclusion criteria: * having backache or wrist pain

Keywords: intubation cardiopulmonary resuscitation manikins
effects of dynamic hyperinflation on the left-ventricular diastolic function in healthy male subjects

Conditions: Pulmonary Disease, Chronic Obstructive

Summary: the aim of this study is to identify whether actively induced dynamic hyperinflation can cause left-ventricular diastolic dysfunction in healthy male subjects in order to explore the mechanisms of developing cardiac dysfunctions in patients with copd.

cardiovascular diseases, especially left-ventricular diastolic dysfunction, are among the most frequent reasons for morbidity and mortality in patients with chronic obstructive pulmonary disease (copd). dynamic hyperinflation is one of the expected pathophysiological mechanisms in the multifactorial genesis of this left-ventricular diastolic dysfunction in patients with copd. the novel concept of expiratory stenosis breathing (esb) is based on the method of metronome-paced tachypnea (mpt) of cooper et al. therefore the investigators use a metronome to indicate a specific breathing frequency (bf) and the relation of inspiration : expiration (i : e) in order to let subjects hyperinflate. subjects get split into two groups each hyperinflating three times for 90sec by one of the two methods before doing a cross-over and switch groups to do the same in the other group. at the end of the 90sec there is a measurement of the inspiratory capacity (ic) and an echocardiography in order to objectify dynamic hyperinflation respectively the change in diastolic function. during esb participants hyperinflate with a bf - 30/min and a i : e - 1 : 3. in addition they have to breathe through an expiratory-effective stenosis (3, 2 and 1,5mm) on the mouthpiece of the pneumotachograph to simulate the collapsing airways in copd-patients. in contrast, during mpt subjects hyperinflate with a bf - 40/min, i : e - 1 : 1; bf - 40/min, i : e - 1 : 2; bf - 30/min, i : e - 1 : 2. during the whole trial investigators measure intrinsic positive endexpiratory pressure (peepi) in order to objectify the dynamic hyperinflation more significantly. the primary goal of this study is to assess if actively induced dynamic hyperinflation can affect diastolic function of the left ventricle. furthermore a correlation between the extent of dynamic hyperinflation and diastolic dysfunction should be quantified. in addition measurement of peepi should validate the method of metronome-paced tachypnea (mpt) because the investigators hypothesize that this method does not simulate the pathophysiological circumstances in patients with copd sufficiently.

Eligibility criteria:
inclusion criteria: * bmi \<27 kg/m2 * lifelong nonsmoker (currently non-smoking and up to now less than 100 cigarettes) exclusion criteria: * obstructive pulmonary diseases (asthma, copd) * cardiovascular diseases (cardiac insufficiency, coronary heart diseases, hypertonia) * other relevant pulmonary or cardiac diseases * baseline e/a-ratio \<1

Keywords: dynamic hyperinflation diastolic dysfunction copd chronic obstructive pulmonary disease metronome-paced tachypnea expiratory-stenosis breathing
capecitabine plus simvastatin in locally advanced rectal cancer patients

Conditions: Adenocarcinoma of Rectum

Summary: statins are widely used as lipid-lowering agents to lower cardiovascular risk with a favorable safety profile. in our recent in vitro study, the addition of simvastatin to chemoradiotherapy with 5-fu showed synergistic anticancer effect in various colon cancer cells (unpublished data). so we planned this study to investigate the synergistic effect of simvastatin combined with capecitabine and radiotherapy in locally advanced rectal cancer patients.

1. primary objective: pathologic complete response rate 2. secondary objectives: 1. rate of sphincter-sparing surgical procedure 2. rate of r0 resection 3. disease-free survival 4. overall survival 5. pattern of failure 6. safety and toxicity 7. lipid lowering effect of simvastatin

Eligibility criteria:
inclusion criteria: * histologically-confirmed adenocarcinoma of rectum * ajcc/uicc clinical stages of ct3-4 or cn+ * age ≥ 20 years * ecog performance status 0-1 * no prior chemotherapy and radiotherapy * adequate major organ functions as following: * written informed consent * willing and able to comply the protocol exclusion criteria: * prior statins therapy within 1-year from the date of study entry * uncontrolled or severe cardiovascular disease : new york heart association class iii or iv heart disease unstable angina or myocardial infarction within the past 6 months history of significant ventricular arrhythmia requiring medication with antiarrhythmics or significant conduction system abnormality. * past or current history (within the last 5 years prior to treatment start) of other malignancies except rectal cancer (patients with curatively treated basal and squamous cell carcinoma of the skin or in situ carcinoma of the cervix are eligible) * uncontrolled systemic illness such as dm, hypertension, hypothyroidism and infection * pregnant nursing women (women of reproductive potential have to agree to use an effective contraceptive method) * patients with cpk \> 5 x uln at baseline * concomitant use with clarithromycin, erythromycin, itraconazole, ketoconazole, nefazodone, telithromycin, gemfibrozil, cyclosporine, danazol, amiodarone, verapamil

Keywords: locally advanced rectal cancer, neoadjuvant chemoradiation
aquacel versus iodoform gauze for filling abscess cavity following incision and drainage

Conditions: Abscess; Cellulitis

Summary: this study compares aquacel against routine iodoform packing for packing abscess cavities after incision and drainage. it is hypothesized that aquacel will produce speedier healing of the abscess.

the large increase in the incidence of skin and soft tissue infections cause by methicillin resistant staphylococcus aureus (mrsa) has produced a corresponding increase in the number of ed patients presenting with abscesses that require incision and drainage. this study compares aquacel against routine iodoform packing for packing abscess cavities after incision and drainage. it is hypothesized that aquacel will produce speedier healing of the abscess. more effective abscess healing will reduce the need for oral antibiotic coverage, which will in turn reduce the potential for drug resistance caused by indiscriminate use of oral antibiotics.

Eligibility criteria:
inclusion criteria: * presenting to maricopa medical center ed with cutaneous abscess requiring incision and drainage exclusion criteria: * known sensitivity to aquacel * pregnant, nursing, or expecting to become pregnant * incarcerated patient * prior treatment of same abscess with incision and drainage * multiple abscesses * immunodeficiency * facial abscess * suspected osteomyelitis or septic arthritis * diabetic foot, decubitis, or ischaemic ulcers * unable to provide informed consent or assent

Keywords: abscess mrsa aquacel dressing iodoform dressing
silver diamine fluoride modified restoration in treating hypomineralized first permanent molar.

Conditions: Molar Incisor Hypomineralization

Summary: a randomized clinical trial to compare silver modified glass ionomer restorations to non silver glass ionomer restorations in hypo-mineralized first permanent molars in children and to measure the amount of wear of restoration in both groups along with detecting changes in hypersensitivity in hypomineralized molars in both groups after one year follow up.


Eligibility criteria:
inclusion criteria: * bilateral first permanent molars affected with molar incisor hypomineralization and with the same icdas ii score. * both chosen molars should be of the same degree of mih severity. exclusion criteria: * signs and symptoms of irreversible pulpitis or pulp necrosis.

Keywords: mih, silver diamine fluoride, children, glass ionomer
validation of a screening test for sarcopenia in older people

Conditions: Sarcopenia

Summary: identify the threshold which the handgrip strenght can be used as a screening test of sarcopenia. handgrip strenght can be used in daily clinical practice to screen patients having sarcopenia to improve treatment and quality of life.

a cross-sectional multicentre study will be performed in hospital and retirement houses on patients ages 75 years old or more.

Eligibility criteria:
inclusion criteria: * ≥ 75 years old exclusion criteria: * palliative care, * protection of vulnerable adults

Keywords: sarcopenia elderly people hospitalization